BioStock: Chordate Medical’s migraine study enters final stage

Since 2018, Chordate Medical has conducted a study on migraine patients to prove clinical efficacy and safety with the nerve modulating treatment method K.O.S. The patient study, conducted in Germany and Finland, is now in its final phase, and the goal is to have an article with the study results submitted to a scientific journal for publication in the spring of 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/chordate-medicals-migraine-study-enters-final-stage/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se